Compare
Petros Pharmaceuticals, Inc. vs Polaryx Therapeutics, Inc. vs Azitra, Inc. vs 60 Degrees Pharmaceuticals, Inc.
| Latest fiscal year | Petros Pharmaceuticals, Inc. PTPI | Polaryx Therapeutics, Inc. PLYX | Azitra, Inc. AZTR | 60 Degrees Pharmaceuticals, Inc. SXTP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $1.01M |
| Revenue growth (YoY) | n/a | n/a | -100.0% | +65.5% |
| Gross margin | n/a | n/a | n/a | 22.3% |
| Operating margin | n/a | n/a | n/a | -771.6% |
| Net margin | n/a | n/a | n/a | -732.5% |
| Net income | $1.91M | -$8.98M | -$10.96M | -$7.37M |
| EPS (Diluted) | -$1.56 | -$0.20 | -$2.25 | -$11.73 |
| Operating cash flow | -$6.73M | -$3.94M | -$11.22M | -$6.85M |
| Free cash flow | n/a | n/a | -$11.25M | -$6.99M |
| Cash & equivalents | $5.14M | $5.14M | $2.07M | $1.51M |
| Total assets | $5.16M | $5.17M | $5.03M | $5.37M |
| Total liabilities | $2.29M | $605.0K | $1.22M | $1.99M |
| Shareholders' equity | $2.87M | $4.57M | $3.80M | $3.46M |
| Return on year-end equity | 66.7% | -196.8% | -288.2% | -212.7% |
| Shares outstanding | 42.28M | 47.34M | 10.74M | 1.16M |
Revenue, most recent five fiscal years
| Fiscal year | Petros Pharmaceuticals, Inc. | Polaryx Therapeutics, Inc. | Azitra, Inc. | 60 Degrees Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $5.11M Ended 2024-12-31 | n/a | $0 Ended 2025-12-31 | $1.01M Ended 2025-12-31 |
| 1 year earlier | $5.82M Ended 2023-12-31 | n/a | $7.5K Ended 2024-12-31 | $607.6K Ended 2024-12-31 |
| 2 years earlier | $5.99M Ended 2022-12-31 | n/a | $686.0K Ended 2023-12-31 | $253.6K Ended 2023-12-31 |
| 3 years earlier | $7.81M Ended 2021-12-31 | n/a | $284.0K Ended 2022-12-31 | $223.2K Ended 2022-12-31 |
| 4 years earlier | $9.56M Ended 2020-12-31 | n/a | n/a | n/a |